CASTLE ROCK, Colo., Aug. 24 /PRNewswire-FirstCall/ -- AspenBio Pharma,
Inc. (OTC Bulletin Board: APNB) an emerging bio-pharmaceutical company
dedicated to the development of novel drugs and diagnostics for animals and
humans, announced today the company has accepted an invitation to present
at the annual Roth Capital Partners New York Investor Conference to be held
September 6th to 7th, 2006. More than 1000 institutional investors are
expected to attend the conference, which will be held at the Westin New
York at Times Square.
AspenBio Pharma president and CEO, Richard Donnelly, is scheduled to
present on Thursday, September 7th, at 8:00 am EST. A simultaneous Webcast
will be available at http://www.wsw.com/webcast/roth8/apnb.ob/.
Roth Capital Partners Investor Conferences are among the largest in the
nation focused on micro and small-cap companies in the Technology,
Healthcare, Financial Services and Consumer Products sectors. For more
information on the conference, please visit the conference website at
http://rothconference.com, or call the conference desk at 800-678-9147. For
media inquiries and press credentials only, call 818-904-0500.
About Roth Capital Partners, LLC
Since 1984, Roth Capital Partners has been a leader and innovator in
the small and micro cap markets. Roth provides the full spectrum of
investment banking services, including raising capital, research coverage,
creating liquidity, trading and market making, merger and acquisition
advisory services, sales support, and investor conferences. Visit
http://www.rothcp.com for more information.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to
the discovery, development, manufacture, and marketing of novel proprietary
products, including those that enhance the reproductive efficiency of
animals and others that have large worldwide market potential. The company
was formed to produce purified proteins for diagnostic applications and has
become a leading supplier of human hormones to many of the nation's largest
medical diagnostic companies and research institutions. The company has
successfully leveraged this foundational science and technology expertise
to rapidly develop an enviable late-stage pipeline of several novel
reproduction hormone analogs for wide-ranging therapeutic use initially in
bovine and equine species. The company has created an early pregnancy "open
cow" diagnostic for dairy cows that is currently in late-stage development.
AspenBio Pharma is also working on a blood test to assist in the diagnosis
of appendicitis in humans. For more information, please visit:
http://www.aspenbiopharma.com.
For more information contact:
AspenBio Pharma, Inc.
Richard Donnelly, CEO 303-794-2000
Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
949-574-3860
SOURCE AspenBio Pharma, Inc.
 back to top
Related links:
http://www.rothcp.com
http://www.aspenbiopharma.com
http://www.rothconference.com
http://www.wsw.com/webcast/roth8/apnb.ob
CONTACT:
Richard Donnelly, CEO of AspenBio Pharma,
Inc., +1-303-794-2000; or Investor Relations, Scott Liolios or
Ron Both, both of Liolios Group, Inc., +1-949-574-3860, for
AspenBio Pharma, Inc.
|
